The newest reporting from every desk, ordered by publication time. New stories appear here immediately after publication.
A newly published randomized trial found better functional recovery with loberamisal after ischemic stroke. An accompanying editorial urges independent replication before drawing broad conclusions.
The investigational peptide did not significantly improve the primary stroke outcome versus placebo. A separate four-patient skin-disease result remains preliminary.
Researchers mapped 61 potentially modifiable risk and protective factors and questioned prevention strategies centered on personal behavior. The analysis supports a broader research agenda but does not establish how much any policy would reduce dementia.
Columbia researchers report that combining p-tau217 with APOE genotype could improve estimates of when cognitive impairment emerges. The observational findings could inform prevention trials, but do not establish a reliable personal countdown to symptoms.
The company announced $62.5 million in financing alongside permission to begin clinical testing of its solid-tumor candidate. Human safety and treatment benefit remain unestablished.
A review of 17 studies found inconsistent results from efforts to connect hospitalized patients with ongoing alcohol treatment. The findings expose uncertainty about discharge strategies, while established treatment remains important for long-term health.
A new analysis applies six protein-based aging clocks to an earlier clinical trial. The findings remain preliminary and cannot establish whether the drug improves healthspan.
A published study pairs semaglutide with low-dose IL-2 to target complementary immune pathways. The findings concern experimental inflammation and do not establish benefit against human neurodegenerative disease.
Human observations and mouse experiments identify a possible link between sodium exposure, inflammation and blood-pressure responses. Whether blocking the pathway can safely help patients remains untested in this study.
A newly published study evaluates Personal-MetaboHealth as a potential prevention tool. Its findings support further testing, but do not establish that improving the score extends healthy life.
The agreement advances a GLP-1 candidate being developed for administration every two weeks. Published trials support further development, while long-term outcomes and European authorization remain unresolved.
The randomized trial tested clinical events over several years in 940 patients. Its neutral result limits claims of additional heart protection while leaving smaller effects and broader aging questions unresolved.